Nephrotic Syndrome
Conditions
Interventions
Rivaroxaban Preventing Group:10mg/d Rivaroxaban on preventing vein thromboembolism
Warfarin Preventing Group:Warfarin targeting INR 2-3 on preventing vein thromboembolism
Sponsors
Peking Union Medical College Hospital, Chinese Academy of Medical Science
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Age: 18-80 years old; (2) Qualitative diagnosis: clinical diagnosis of nephropathy syndrome; (3) At least one of the following high coagulation tendencies combined: plasma albumin less than 25 g/L, membrane nephropathy, past history of venous thrombosis, a family history of venous thrombosis; (4) Calculated glomerular filtration rate more than 30 ml/min; (5) The patient and family members understand the purpose of the research well and are willing to participate in the study and provide written informed consent.
Exclusion criteria
Exclusion criteria: (1) Cancer with expected survival period fewer than 6 months; (2) Serious liver disease; (3) Surgery is required in the near future; (4) Pregnant or lactating women; (5) Vascular ultrasound examination found that there is an existing venous thrombosis; (6) Contraindication of anticoagulation treatment of Rivaroxaban or Warfarin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Combined incidence of bleeding events (including mild and severe bleeding events) and thrombosis events within 6 months after anticoagulant treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cost of anticoagulant-related therapy within 6 months after anticoagulant therapy;Complete and partial remission rate of nephrotic syndrome within 6 months after anticoagulant treatment; | — |
Countries
China
Contacts
Public ContactChen Gang
Peking Union Medical College Hospital, Chinese Academy of Medical Science
Outcome results
None listed